The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of age on treatment outcome to palonosetron (PALO) plus 1-day dexamethasone (DEX) for the prevention of nausea and vomiting in women receiving anthracycline plus cyclophosphamide (AC)-based chemotherapy: A meta-analysis of two phase III trials.
L. Celio
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics
E. Bonizzoni
No relevant relationships to disclose
E. Bajetta
No relevant relationships to disclose
S. Sebastiani
Employment or Leadership Position - Helsinn Therapeutics
T. Perrone
Employment or Leadership Position - Italfarmaco
M. S. Aapro
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics